Adam J. Gadzinksi, MD, MS, on the Impact of Telemedicine on Patient-Reported Outcomes

Video

The study assessed the impact of a rurally focused telemedicine program on patient outcomes in the urologic oncology outpatient clinic at the University of Washington Medical Center.

Findings from a study presented at the Society of Urologic Oncology 21st Annual Meeting revealed the impact of a rurally focused telemedicine program on patient outcomes in the urologic oncology outpatient clinic at the University of Washington Medical Center (UWMC).

The investigators ultimately discovered that telemedicine provides a medium for cancer care delivery that eliminates the significant travel burden associated with in-person clinic appointments.

In an interview with CancerNetwork®, Adam J. Gadzinski, MD, MS, urologic oncology fellow and an acting instructor of Urologic Oncology at the Urology Clinic at UWMC, explained the implications of these study results.

Transcription:

I think for us, what we really took out of this was that patients were spending a lot just to come and see us in clinic. And that telemedicine, in terms of at least the outcomes of patient satisfaction, really was equivalent to in person visits. We had very complex discussions about very challenging cancer issues and decisions that patients had to make. And I think we found that having those discussions over telemedicine was pretty darn similar to in person visits.

And for certain parts of urologic cancer care, physical exam is not always the kind of hinge point of a decision and so you don't have to examine someone when you have their CT scan that you can review with them. You know, maybe they don't need to drive from eastern Washington 5 hours for you to, to you know, lay your hands on their abdomen and then look at the CT scan with them and make all of your cancer treatment decisions based on the CT scan.

There are some patients you do have to kind of see them in person and examine them in person before you decide on treatment decisions. And sometimes what we found is the telemedicine really streamlined their in person visit when they did come, so then when they come they're also getting, you know, a repeat CT scan, they’re getting labs, and so their trip to Washington, to Seattle, was more of a implementing a plan and less kind of discovering what that plan might be.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Related Content